Lead candidate Telomir-1 reverses aging markers, restores muscle mass, and boosts survival in genetic progeria model
Telomir Pharmaceuticals (TELO), a rising innovator in age-reversal science, has announced new preclinical data showing that its lead drug candidate, Telomir-1, dramatically reverses key aging markers in a vertebrate model of Werner Syndrome (WS), a rare genetic disorder often referred to as adult-onset progeria.
In a 14-day study using a genetically validated zebrafish model of WS, Telomir-1 delivered a range of compelling results: it significantly elongated telomeres, reversed muscle and body weight loss, restored proper gene regulation through epigenetic repair, reduced oxidative stress, and improved survival rates.
Werner Syndrome is caused by mutations in the wrn gene, which plays a crucial role in DNA repair and telomere maintenance. Patients typically experience accelerated aging symptoms—graying hair, diabetes, osteoporosis, and cardiovascular complications—in their 20s or 30s, with a median life expectancy of just 40–50 years. Currently, there are no FDA-approved treatments.
Key Findings:
- DNA Methylation Reversal: Telomir-1 successfully reset age-related DNA methylation patterns at two chromosomal regions, restoring gene regulation and potentially lowering the risk of diseases like cancer, Alzheimer’s, and autoimmune disorders.
- Telomere Elongation: The drug increased telomere length by approximately three-fold, surpassing even healthy control levels at higher doses. Telomere restoration is seen as a crucial step in combating cellular aging.
- Muscle and Weight Recovery: Zebrafish with the wrn mutation exhibited 50–60% reductions in muscle volume and weight. After Telomir-1 treatment, these metrics returned to levels indistinguishable from healthy animals.
- Oxidative Stress Reduction: Reactive oxygen species (ROS), a major driver of cellular aging, were reduced by up to 50%.
- Survival Advantage: While 15% of untreated animals died during the study, none of the Telomir-1-treated fish died, indicating a systemic benefit.
“This may be one of the most important developments in the field of aging,” said CEO Erez Aminov. “The consistency and strength of the data demand serious attention.”
Dr. Itzchak Angel, Chief Scientific Advisor, added: “Telomir-1’s ability to restore both genomic and epigenetic stability makes it a promising candidate for a foundational anti-aging therapy.”
You might like this article:Amazon to Invest $10 Billion in North Carolina to Expand AI Infrastructure
